Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
From the docket
Litigation Timeline
- July 2026
Public Search Interest in Zantac Lawsuit Topics Spikesscientific
Google Trends data detected sharp increases in searches for terms including 'ranitidine' (up 300%), 'zantac lawsuit attorneys' (up 150%), and 'ndma' (up 170%), along with breakout search activity for 'zantac lawsuit update 2022' and 'recall on zantac,' according to Google Trends.
- July 24, 2026
Public Search Interest in Zantac and NDMA Terms Rises Sharplyscientific
Google Trends data recorded a sharp week-over-week rise in searches for 'ranitidine' (+300%), 'zantac lawsuit attorneys' (+150%), and 'ndma' (+170%), along with breakout search activity for 'zantac lawsuit update 2022,' 'cetirizine recall,' and 'recall on zantac.'
- June 2026
Search Interest in Zantac Lawsuits and Recalls Spikes Sharplyfiling
During the week of June 24, 2026, Google Trends recorded major increases in searches related to Zantac recalls, ranitidine, and NDMA — including a 250% week-over-week rise in searches for 'zantac lawsuit attorneys' and 'ndma,' a 130% rise in 'recall on zantac,' and breakout-level growth in 'zantac lawsuit update 2021' and 'zantac lawsuit update 2022.' These trend signals suggest renewed public attention to the ongoing Zantac litigation landscape.
- June 2026
Zantac-Related Search Terms Spike Sharply on Google Trendsfiling
Google Trends data detected week-over-week surges in several Zantac-related search terms around June 24, 2026. Searches for 'zantac lawsuit attorneys' rose 250%, 'ndma' rose 250%, and 'ranitidine' rose 100%. Terms including 'recall on zantac,' 'zantac lawsuit update 2021,' and 'zantac lawsuit update 2022' were flagged as BREAKOUT trends, meaning search volume increased so sharply that a standard percentage could not be calculated.
- 2023–2026 (ongoing)
State Court Litigation Continues — Delaware and California, 2026litigation
Following the closure of the federal MDL, Zantac litigation has migrated to and continues actively in state courts. Delaware Superior Court has emerged as the primary consolidated venue, with thousands of cases proceeding under coordinated case management orders. California state courts also have active Zantac dockets. Plaintiffs' attorneys have developed refined expert testimony — addressing the methodological criticisms raised in the federal Daubert ruling — specifically tailored to state court evidentiary standards. State courts are not bound by the federal Daubert standard or by Judge Rosenberg's 2022 ruling. Cases involving bladder, stomach, colorectal, and esophageal cancer have proceeded furthest in state court litigation. In 2026, new state court filings continue to be accepted in Delaware and California for claimants with qualifying diagnoses within applicable statutes of limitations.
- November 2022
Federal MDL Dismissed on Daubert Grounds — November 2022litigation
Judge Robin L. Rosenberg of the U.S. District Court for the Southern District of Florida issued an order granting defendants' Daubert motions and excluding all of the plaintiffs' general causation expert witnesses in MDL No. 2924 (In re: Zantac (Ranitidine) Products Liability Litigation). The court found that plaintiffs' experts relied on methodologies that were unreliable under federal evidentiary standards, including flawed use of epidemiological data and improper extrapolation from animal studies. Without admissible general causation expert testimony, plaintiffs could not meet their burden of proof, and the MDL was effectively dismissed. The Eleventh Circuit upheld the dismissal. This ruling applies only to federal court proceedings and does not bind state courts, which use their own expert evidentiary standards.
- April 1, 2020
FDA Orders Zantac Market Withdrawal — April 2020regulatory
The FDA formally requested all manufacturers of prescription and OTC ranitidine products to immediately withdraw their products from the U.S. market, effective April 1, 2020. The FDA stated that its testing found that NDMA levels in ranitidine products increase over time and under certain storage conditions, and that the agency could not identify a way to stabilize ranitidine to prevent NDMA formation. This market withdrawal applies to all ranitidine products from all manufacturers — Sanofi (Zantac brand), GSK, Pfizer, Boehringer Ingelheim, and all generic and store-brand versions. This date is significant for statute of limitations purposes, as it placed the public on notice of the NDMA-ranitidine connection.
- June 2019
Valisure 2019 Study — NDMA in Ranitidine Discoveredregulatory
In June 2019, independent pharmaceutical testing laboratory Valisure LLC filed a Citizen Petition with the FDA reporting NDMA levels of up to 304,500 nanograms per ranitidine tablet — more than 3,000 times the FDA's acceptable daily intake limit of 96 nanograms. Valisure demonstrated that ranitidine is inherently unstable and generates NDMA as a degradation product, with levels increasing at higher temperatures. This petition triggered FDA investigations and independent scientific studies confirming the NDMA-ranitidine link and establishing that NDMA is generated in the human body following ranitidine ingestion.
- Pre-2019
Long-Term Zantac Use — Minimum 1 Year Requiredqualifying
To qualify for a Zantac cancer claim, claimants generally must demonstrate at least one year of consistent Zantac (ranitidine) or generic ranitidine use. This threshold is based on the pharmacokinetic evidence showing that meaningful NDMA exposure accumulates with sustained use over time. Both prescription ranitidine and OTC Zantac (widely available since 1996) qualify. Evidence of use includes pharmacy prescription records, insurance claims data, store loyalty card purchase records, and patient testimony corroborated by treating physician records showing ranitidine prescriptions or OTC use documented in medical history.
Stay informed
Get free updates on the Zantac / Ranitidine (NDMA Cancer) litigation as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Full case details
Want the complete picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View the full Zantac / Ranitidine (NDMA Cancer) case page →